AXIS CAPITAL HOLDINGS LTD Overview
Industry: Insurance Specialty
Sector: Financial Services
AXIS Capital Holdings Limited, through its subsidiaries, provides various specialty insurance and reinsurance products worldwide. It operates through two segments, Insurance and Reinsurance. The Insurance segment offers property insurance products for commercial buildings, residential premises, construction projects, and onshore energy installations; marine classes covering offshore energy, cargo, liability, kidnap and ransom, fine art, specie, and hull war; and terrorism, aviation, credit and political risk, and liability insurance products. It also provides professional insurance products that cover directors' and officers' liability, errors and omissions liability, employment practices liability, fiduciary liability, crime, professional indemnity, medical malpractice, and other financial insurance related coverages for commercial enterprises, financial institutions, not-for-profit organizations, and other professional service providers. In addition, this segment offers accidental death, travel, and specialty health products for employer pet insurance and affinity groups. The Reinsurance segment offers reinsurance products to insurance companies, including catastrophe reinsurance products; property reinsurance products covering property damage and related losses resulting from natural and man-made perils; professional lines; credit and surety; and motor liability products. This segment also provides agriculture reinsurance products; engineering coverages for various types of construction risks and risks related to erection, testing, and commissioning of machinery and plants during the construction stage; marine and aviation reinsurance products; and personal accident, specialty health, accidental death, travel, life, and disability reinsurance products. AXIS Capital Holdings Limited was founded in 2001 and is headquartered in Pembroke, Bermuda. AXIS Capital Holdings Limited, through its subsidiaries, provides various specialty insurance and reinsurance products worldwide. It operates through two segments, Insurance and Reinsurance. The Insurance segment offers property insurance products for commercial buildings, residential premises, cons Read MoreMavefund brings filings, fundamentals, valuation, price history and news for AXIS CAPITAL HOLDINGS LTD into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $1.6B (+8% YoY). Operating income was $257M.
What changed
- Revenue +8% YoY to $1.6B.
- Operating income (1) for the first quarter of 2026 was $257 million, a decrease of $5 million, or 2%, compared to the first quarter of 2025.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
What AXIS Capital Holdings (AXS)'s Anticipated Revenue Reacceleration And Earnings Release Means For Shareholders
Headline from Yahoo Finance Australia: What AXIS Capital Holdings (AXS)'s Anticipated Revenue Reacceleration And Earnings Release Means For Shareholders.
Axis Capital (AXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Headline from Yahoo Finance: Axis Capital (AXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release.
Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance
Headline from Yahoo Finance: Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance.
Axsome gets FDA filing acceptance for narcolepsy drug AXS-12 By Investing.com
Headline from Investing.com South Africa: Axsome gets FDA filing acceptance for narcolepsy drug AXS-12 By Investing.com.
Axsome gets FDA filing acceptance for narcolepsy drug AXS-12
Headline from Investing.com: Axsome gets FDA filing acceptance for narcolepsy drug AXS-12.
Axsome gets FDA filing acceptance for narcolepsy drug AXS-12 By Investing.com
Headline from Investing.com UK: Axsome gets FDA filing acceptance for narcolepsy drug AXS-12 By Investing.com.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.